2 weeks Ago By ABMN Staff
Pulmatrix, Inc. ( NASDAQ:PULM – Get Free Report ) saw a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 6,400 shares, a growth of 25.
5% from the August 31st total of 5,100 shares. Approximately 0.2% of the company’s stock are short sold.
Based on an average daily volume of 12,200 shares, the short-interest ratio is currently 0.5 days. Pulmatrix Price Performance Shares of PULM traded up $0.
11 during mid-day trading on Friday, reaching $2.14. The company had a trading volume of 5,541 shares, compared to its average volume of 10,141.
The company’s 50-day moving average is $2.10 and its 200-day moving average is $1.98.
Pulmatrix has a twelve month low of $1.55 and a twelve month high of $2.75.
The company has a market capitalization of $7.81 million, a P/E ratio of -0.89 and a beta of 0.
99. Pulmatrix ( NASDAQ:PULM – Get Free Report ) last posted its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.
87) earnings per share for the quarter. Pulmatrix had a negative net margin of 95.18% and a negative return on equity of 46.
86%. The company had revenue of $1.55 million during the quarter.
Wall Street Analyst Weigh In Check Out Our Latest Stock Analysis on PULM About Pulmatrix ( Get Free Report ) Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. Featured Stories Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.
com's FREE daily email newsletter ..
